Drug Profile
Research programme: GPR119 protein agonists - Metabolex
Latest Information Update: 20 Dec 2013
Price :
$50
*
At a glance
- Originator Metabolex
- Developer CymaBay Therapeutics
- Class Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 10 Dec 2013 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 28 Apr 2011 GPR119 protein agonists are no longer licensed to sanofi-aventis worldwide
- 28 Jun 2010 Metabolex and sanofi-aventis enter into a global licensing agreement for discovery, development, manufacture and commercialisation of small molecule GPR 119 agonists for the treatment of type 2 diabetes ,